MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: We show for the first time that combination of SFK, MEK, and NF‐κB cascade inhibitors significantly reduces survival of IM‐resistant cells and IM‐insensitive CML CD34+ cells.